KALA BIO (DE:27F)

FRANKFURT:27F

27F

KALA BIO

RESEARCH TOOLSreports

KALA BIO (27F) Price & Analysis

0 Followers

27F Stock Chart & Stats

€0.47

€0.02(0.21%)

At close: Jan 08 4:00 PM EST

€0.47

€0.02(0.21%)

Day’s Range― - ―

52-Week Range€3.40 - €849.50

Previous CloseN/A

VolumeN/A

Average Volume (3M)72.00

Market Cap

€35.86M

Enterprise Value€47.14M

Total Cash (Recent Filing)€8.76M

Total Debt (Recent Filing)€0.00

Price to Earnings (P/E)―

Beta1.23

Next Earnings

Aug 06, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-2.96

Shares Outstanding18,589,832

10 Day Avg. Volume0

30 Day Avg. Volume72

Financial Highlights & Ratios

PEG Ratio0.16

Price to Book (P/B)32.38

Price to Sales (P/S)0.00

P/FCF Ratio-7.08

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-22.53

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Improved Leverage: Debt Reduced To ZeroDebt reduction to zero materially lowers near-term default and interest risks, improving financial flexibility to fund R&D or negotiate partnerships. A cleaner balance sheet lengthens runway options and makes non-dilutive deals or asset transactions more feasible as strategic choices.

Exclusive AI-platform Licensing InitiativeAccess to an AI biomedical research platform can structurally enhance discovery and preclinical productivity, reducing time and cost per candidate. If integrated successfully, the platform could create repeatable R&D advantages and enable partnering or licensing revenue streams beyond one-off trial outcomes.

Clinical-stage, Antibody-focused PipelineA clinical-stage, antibody-centric pipeline targets large, durable autoimmune markets and reflects specialized scientific capabilities. Progress in clinical stages creates discrete value inflection points and makes the company attractive for strategic partnerships or acquisitions, supporting long-term upside independent of market noise.

Bears Say

Zero Revenue BaseWith no product revenue, the business lacks operating cash generation and must rely entirely on financing and collaborations. This removes margin insulation and makes program continuity contingent on external funding, increasing binary outcome risk around trial results and partner deals.

Persistent, Accelerating Cash BurnSustained negative operating and free cash flow indicates an accelerating funding requirement that pressures liquidity and forces financing decisions. Recurrent burn reduces strategic optionality, raises probability of dilutive raises, and can disrupt multi-year clinical programs if capital access tightens.

Material Dilution And Financing Pressure From DealIssuing significant shares as part of the licensing arrangement reduces existing ownership and signals reliance on equity to fund operations. Repeated equity-based financing erodes per-share value, can weaken executive ownership incentives, and increases sensitivity to future financing market conditions.

27F FAQ

What was KALA BIO’s price range in the past 12 months?

KALA BIO lowest stock price was €3.40 and its highest was €849.50 in the past 12 months.

What is KALA BIO’s market cap?

KALA BIO’s market cap is €35.86M.

When is KALA BIO’s upcoming earnings report date?

KALA BIO’s upcoming earnings report date is Aug 06, 2026 which is in 62 days.

How were KALA BIO’s earnings last quarter?

KALA BIO released its earnings results on May 19, 2026. The company reported -€0.117 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.117.

Is KALA BIO overvalued?

According to Wall Street analysts KALA BIO’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does KALA BIO pay dividends?

KALA BIO does not currently pay dividends.

What is KALA BIO’s EPS estimate?

KALA BIO’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does KALA BIO have?

KALA BIO has 18,589,832 shares outstanding.

What happened to KALA BIO’s price movement after its last earnings report?

KALA BIO reported an EPS of -€0.117 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of KALA BIO?

Currently, no hedge funds are holding shares in DE:27F

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

KALA BIO Stock Smart Score

Underperform

Technicals

Fundamentals

Return on Equity

-1335.64%

Trailing 12-Months

Asset Growth

-74.47%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

KALA BIO

Kala Bio, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of therapeutics using proprietary nanoparticle-based mucus penetrating particles with an initial focus on the treatment of eye diseases. The company was founded by Justin Hanes, Robert S. Langer and Colin R. Gardner in 2009 and is headquartered in Arlington, MA.